Cadila Healthcare’s Baddi facility receives EIR from USFDA

06 Jun 2017 Evaluate

Cadila Healthcare’s formulations manufacturing facility at Baddi has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). This receipt of EIR indicates the successful closure of the inspection points (483s) raised based on the inspection carried out between February 21, 2017 to March 01, 2017.

Recently, the company’s Topical manufacturing located at Changodar was successfully inspected by USFDA from April 3 to April 7, 2017. At the end of the inspection, no observation (483) was issued. The company had filed 17 products with the USFDA from this manufacturing facility.

Cadila Healthcare is part of the Zydus Cadila Group. The company operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world.



Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×